top of page

Pro PG receives S19A approval for - Ozempic 0.25mg & 0.5mg solution for injection in pre-filled pen

Dear Healthcare Professional,

ree

OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen AUST R: 308324 - shortage and alternative supply arrangement


Pro Pharmaceuticals Group (ProPG) advises that due to a shortage of Australian registered OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen AUST R: 308324.


ProPG has arranged for an alternative product Ozempic 0.25mg & 0.5mg solution for injection in pre-filled pen (USA) . The S19A product is registered and marketed in the USA and the supply is authorized under an exemption granted by the TGA under Section 19A of the Therapeutic Goods Act, 1989 until 30th September 2022.




 
 
Recent Posts
Archive
Search By Tags
Follow Us
  • Twitter Social Icon
  • Google+ Basic Square

TEL:

1300 077 674 (1300 0 PRO PG)

FAX:

(03) 86790397

AUSTRALIA​      |  GERMANY  |      POLAND

Legal & Trademark Notice
© 2025 Pro Pharmaceuticals Group Pty Ltd. All rights reserved.
Pro PG, CheckMed, and their respective logos are registered trademarks owned worldwide by Pro Pharmaceuticals Group Pty Ltd.
Pro Pharmaceuticals Group operates globally through associated entities, including CTS Pharmaceuticals Pty Ltd (Australia), Jemstar Sp. z o.o. (Poland), and Pro Pharmaceuticals Group NZ Ltd (New Zealand).

International Tax Registrations:
ABN 20 605 457 430 (Australia) | VAT DE401757398 (EU VAT ID) | Steuernummer 15/460/00493 (Germany) | VAT PL5263362401 (Poland) | VAT NL825524295B01 (Netherlands).

bottom of page